| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
3′-Deoxyuridine targets viral replication, specifically inhibiting bovine diarrhoea virus (BVDV) production. As a nucleoside analog, it may interfere with viral DNA or RNA synthesis by acting as a chain terminator or by inhibiting viral polymerases. Its potential anticancer activity is also attributed to its effects on nucleic acid synthesis.
|
|---|---|
| ln Vitro |
3′-Deoxyuridine demonstrates in vitro antiviral activity by inhibiting bovine diarrhoea virus production. It is a potential anticancer agent. The compound's activity is consistent with its classification as a nucleoside antimetabolite.
|
| ln Vivo |
In vivo activity of 3′-deoxyuridine has not been extensively documented. Its potential as an anticancer and antiviral agent suggests possible in vivo efficacy, but further studies are needed to evaluate its pharmacokinetic properties and therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme assays for 3′-deoxyuridine involve measuring its effects on viral polymerases or its incorporation into nucleic acids. The compound's ability to inhibit BVDV production can be assessed using cell-based antiviral assays.
|
| Cell Assay |
In vitro cellular assays for 3′-deoxyuridine involve treating virus-infected cells or cancer cell lines with varying concentrations of the compound. Antiviral activity is assessed by measuring viral replication. Anticancer activity is assessed by measuring cell proliferation using MTT or other assays.
|
| Animal Protocol |
In vivo animal experiments for 3′-deoxyuridine are not extensively documented. If used in animal models, typical protocols would involve administering the compound to virus-infected or tumor-bearing animals and evaluating efficacy by measuring viral load or tumor growth. Further studies are needed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 3′-deoxyuridine are limited. As a nucleoside analog, its absorption, distribution, metabolism, and excretion properties would influence its bioavailability. Further pharmacokinetic studies are needed to determine its systemic exposure.
|
| Toxicity/Toxicokinetics |
Toxicological data for 3′-deoxyuridine are limited. As a nucleoside analog, it may have potential for toxicity at higher concentrations. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only.
|
| References |
[1]. Lin TS, et al. Synthesis and anticancer activity of various 3'-deoxy pyrimidine nucleoside analogues and crystal structure of 1-(3-deoxy-beta-D-threo-pentofuranosyl)cytosine. J Med Chem. 1991;34(2):693-701.
|
| Additional Infomation |
3′-Deoxyuridine (CAS#: 7057-27-4) has the molecular formula C9H12N2O5 and a molecular weight of 228.20 g/mol. It is a pyrimidine nucleoside analog with potential anticancer and antiviral activity. The compound inhibits bovine diarrhoea virus production.
|
| Molecular Formula |
C9H12N2O5
|
|---|---|
| Molecular Weight |
228.20
|
| Exact Mass |
228.074
|
| CAS # |
7057-27-4
|
| PubChem CID |
145984
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Melting Point |
176-177℃
|
| Index of Refraction |
1.603
|
| LogP |
-1.75
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
343
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O=C1NC(C=CN1[C@@H]2O[C@H](CO)C[C@H]2O)=O
|
| InChi Key |
QOXJRLADYHZRGC-SHYZEUOFSA-N
|
| InChi Code |
InChI=1S/C9H12N2O5/c12-4-5-3-6(13)8(16-5)11-2-1-7(14)10-9(11)15/h1-2,5-6,8,12-13H,3-4H2,(H,10,14,15)/t5-,6+,8+/m0/s1
|
| Chemical Name |
1-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (219.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.96 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.96 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.96 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.3821 mL | 21.9106 mL | 43.8212 mL | |
| 5 mM | 0.8764 mL | 4.3821 mL | 8.7642 mL | |
| 10 mM | 0.4382 mL | 2.1911 mL | 4.3821 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
